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Pediatric coronavirus disease – 19 (COVID-19) infection is relatively mild when compared to 
adults, and children are reported to have a better prognosis. Mortality in children appears rare. 
Clinical features of COVID-19 in children include fever and cough, but a large proportion of 
infected children appears to be asymptomatic and may contribute to transmission. It remains 
unclear why children and young adults are less severely affected than older individuals, but 
this might involve differences in immune system function in the elderly and/or differences in 
the expression/function of the cellular receptor for Severe Acute Respiratory Syndrome 
Coronavirus 2 (SARS-CoV-2) - Angiotensin converting enzyme 2 (ACE2). Laboratory 
findings and chest imaging may not be specific in children with COVID-19. Diagnosis is by 
Reverse transcriptase-Polymerase chain reaction (RT-PCR) testing of upper or lower 
respiratory tract secretions. This review additionally considers COVID-19 in 
immunosuppressed children, and also suggests a management algorithm for the few children 
who appear to present with life threatening infection, including the potential use of antiviral 
and immunomodulatory treatment. The most significant threat to global child health from 
SARS-CoV-2 is unlikely to be related to COVID 19 in children, but rather the socio-economic 
consequences of a prolonged pandemic. 















Coronavirus disease -19 (COVID-19) is a global health crisis. The clinical characteristics, 
disease progression and outcome in children and young adults appear significantly milder 
compared to older individuals. Since first being reported in Wuhan, China in December 2019, 
COVID-19 has rapidly spread to affecting over 200 countries worldwide. Children account for 
1-5% of diagnosed COVID-19 cases [1]; although, many infected children may be 
asymptomatic and therefore not diagnosed without population screening. At the time of 
writing, in India, the number of virologically confirmed COVID-19 positive cases is 5273 as 
per the Ministry of Health and Family Welfare (MOHFW) [2]. 149 deaths have been reported 
from India so far.  
VIROLOGY AND EPIDEMIOLOGY  
Coronaviruses are a family of enveloped, single stranded, zoonotic RNA viruses which can 
rapidly mutate and recombine, leading to novel viruses that can spread from animals to 
humans [3]. The precise events that led to the emergence of Severe Acute Respiratory 
Syndrome Coronavirus-2 (SARS-CoV-2) causing COVID-19 remain unknown. SARS-CoV-2 
is transmitted through inhalation of respiratory droplets of an infected person and touching 
surfaces contaminated with the virus. In previous coronavirus epidemics, children globally 
accounted for 6.9% of SARS 2002-3 infections and 2% of Middle East Respiratory Syndrome 
(MERS) infections. It appears that SARS-CoV-2 has a higher transmission capability 
compared with the closely related viruses causing Severe Acute Respiratory Syndrome 2002-3 
(SARS 2002-3) and MERS [4]. The true case fatality rate (CFR) of COVID-19 infection is 
currently unknown due to lack of population-scale longitudinal data. Thus, estimates of CFR 







The SARS-CoV-2 virus utilizes Angiotensin Converting Enzyme2 (ACE2) receptors as its cell 
surface receptor, similar to the SARS 2002-3 virus. ACE2 is expressed highly by ciliated 
epithelial cells in the human lungs and this receptor allows the virus to attach to the cell [6]. 
The ACE2 receptor is also expressed in the intestines, potentially accounting for the 
gastrointestinal symptoms that commonly occur in the early stage of the illness.  
Severe COVID-19 disease is characterised by three phases: the first being the viral 
phase; the second being the cytokine storm; and the third encompassing acute respiratory 
distress syndrome (ARDS), impaired cardiac function and death [7]. The cytokine storm 
appears to be driven by a dysregulated host immune response [8] and might contribute to 
mortality [9]. The profile of the cytokine storm associated with severe COVID-19 disease is 
similar to that of secondary hemophagocytic lymphohistiocytosis (HLH), which is a rare 
complication of other viral infections (3.7-4.3%) [8]. Secondary HLH is characterised by 
fulminant and fatal hypercytokinemia with multiorgan failure. In severe infection, lower 
peripheral lymphocyte counts (CD4 and CD8 T cells), higher interleukin (IL) levels (IL-6 and 
IL-10), decreased interferon-gamma expression in CD4+ T cells and higher D-dimer and 
fibrin degradation products (FDP) levels, leading to increased thrombosis and multiorgan 
injury has been described. Moreover, patients with severe infection may also have abnormal 
coagulation parameters, perhaps related to high expression of ACE2 receptors in vascular 
endothelial cells. 
Transmission 
Most infected children are likely to be secondary cases and acquire the infection after 
exposure to a COVID-19 positive adult, although there are no longitudinal data to confirm this 
yet. Intrafamily transmission may be important [10]. An as yet unquantified proportion of 




whether COVID-19 is acquired by contact with infected feces [10,11]. In a report of 10 
children admitted for COVID-19 with positive nasopharyngeal swabs, 8 of 10 children 
demonstrated persistently positive real time reverse transcriptase - polymerase chain reaction 
(RT-PCR) of rectal swabs after their nasopharyngeal testing had become negative [12]. It 
remains unclear whether the detection of virus by RT-PCR in fecal matter represents active 
viral replication or residual viral genomic material, however, it appears that viral shedding 
from the digestive tract might be greater and last longer than that from the respiratory tract 
[12].  
Why is Covid-19 Milder in Children? 
Multiple reports have demonstrated that children and young adults have a milder form of the 
disease compared to adults [13]. Asymptomatic, mild and moderate infections comprise over 
90% of all children who have tested positive for COVID-19 with fewer severe and critical 
cases (5.9%) compared to adults (18.5%) [13]. The possible reasons for lower number and 
milder infections in children and young adults include lower exposure to virions, being 
isolated at home and minimal exposure to pollution and cigarette smoke contributing to 
healthier respiratory tracts. The elderly may be susceptible to severe COVID-19 disease by 
their qualitatively different immune response, encompassed by the terms ‘immunosenescence’ 
and ‘inflammaging’ [14]. Viral co-infection may be important in potentially leading to limited 
replication of the SARS-CoV-2 by direct virus-to-virus interaction and competition [15]. 
Additionally, the distribution, maturation and functioning of viral receptors such as ACE2 
may be important in age-dependent susceptibility to severe COVID-19 [13,16].  
Due to smaller number of reported cases in children, it is at present challenging to 
delineate the clinical characteristics of children with severe COVID-19 infection, combined 
with the lack of a clear biomarker to indicate severity of infection[17]. Dong et al, in the 




children were asymptomatic [13]. This makes epidemiological inference problematic since 
asymptomatic children are less likely to be tested and may still contribute to transmission. In 
addition, a significant proportion of children can also have co-infections with other viruses, 
and the detection of SARS-CoV-2 may therefore be clinically insignificant [11]. It has been 
proposed that the outcome for some children may be worse due to exposure to antenatal 
smoking and obesity [17]. 
Another theory that has been postulated is the protective role of Bacillus Calmette-
Guerin (BCG) vaccine in COVID-19. BCG vaccination has been associated with heterologous 
immunity to other pathogens, potentially by a phenomenon called ‘trained immunity’ 
involving innate cells such as macrophages, monocytes and epithelia [18]. Trials are underway 
to understand if BCG vaccination may offer protection against COVID-19.  
 
CLINICAL FEATURES 
Children of all ages can be infected with COVID-19, with more cases reported in younger 
children and infants [13]. Acknowledging the possible reporting biases discussed above, there 
is no age or sex preponderance [13] and the median age of infection is 6.7 years (range - 
newborn to 15 years) [19]. The incubation period of COVID-19 in children has been reported 
as 2 days (range - 2 to 10 days) [1]. At the time of diagnosis, 13-15% of virologically positive 
children may be asymptomatic [13,19]. The most common symptoms described at onset in 
children are fever (50%) and mild cough (38%) [10]. Fever is present in about 40 % of 
children[19].Other clinical features include sore throat, rhinorrhoea, sneezing, myalgia, 
fatigue, diarrhoea and vomiting. Children may have more upper respiratory symptoms than 





Risk Stratification and Severity Classification 
In the largest pediatric cohort to date, Dong, et al. [13] describe suspected and confirmed 
cases based on symptoms, laboratory abnormalities, chest imaging, and RT-PCR/genomic 
analysis. The severity of COVID-19 was divided into asymptomatic, mild, moderate, severe 
and critical. Severe COVID-19 accounted for 18 (2.5%) of virologically confirmed cases, and 
furthermore the definition of severe included children with only mild hypoxia. Critical 
COVID-19 was observed in 3(0.4%) of virologically confirmed cases, defined by the presence 
of ARDS or organ failure. Though data on chronology of complications and predictors of 
mortality is available in adults, there is insufficient data on predictors of mortality in children. 
 
DIAGNOSTIC TECHNIQUES  
The Ministry of Health and Family Welfare (MOHFW) [2] in their updated guidelines (as of 
7th April, 2020) has categorized patients into three groups – those with mild, moderate and 
severe illness, and have designated COVID dedicated facilities for their treatment. 
RT-PCR testing of nose and throat swab for detection of SARS-CoV-2 nucleic acid 
has been recommended as the confirmatory test for COVID-19 [21]. Other alternative samples 
for RT-PCR include bronchoalveolar lavage or endotracheal aspirate. The Government of 
India has now advised the use of antibody tests in patients with symptomatic influenza-like 
illness (ILI) in 25 districts across the country, or ‘COVID hotspots’ [22]. Based on the results 
of the antibody test, confirmatory RT-PCR and clinical assessment, hospital treatment or 
home isolation measures are instituted, with contact tracing measures as per protocol. 
The limited data in children describes relatively lower rates of lymphopenia and 
elevated inflammatory markers compared to adults [1]. Henry et al summarised findings from 




neutrophilia (4.6%) and lymphopenia (3.0%). C reactive protein (CRP) and procalcitonin were 
high only in 13.6% and 10.6% of cases, respectively. Slight elevation of liver transaminases is 
common [23]. It is recommended to monitor the lymphocyte count and CRP as signs for 
severe infection, while using procalcitonin levels to detect potential bacterial co-infection [23]. 
Chest X-ray findings in children appear to be non-specific. Children with mild disease 
should not routinely need computed tomography (CT) chest imaging in view of the high 
radiation exposure [24]. When CT is performed, ground glass opacities is seen in one third of 
patients [19]. Peripheral distribution of lung lesions has been noted, with multilobar 
involvement [25]. Consolidation with surrounding halo sign is considered typical of pediatric 
patients [26]. However, chest CT alone cannot accurately diagnose COVID-19 due to similar 
radiological presentations with other infections. 
Patients admitted with severe infection are known to have elevated plasma levels of 
IL-2, IL-7, IL-10, granulocyte colony stimulating factor (GCSF), interferon-gamma-inducible 
protein 10 (IP10), monocyte chemoattractant protein 1 (MCP1), macrophage inflammatory 
protein 1-alpha (MIP1A) and tumour necrosis factor (TNF) alpha [9]. In a study comprising of 
150 confirmed COVID-19 cases in Wuhan, China, elevated ferritin (mean 1298 ng/mL vs 614 
ng/mL; P<0.001) and IL-6 levels (P <0.0001) were found in survivors compared to non- 
survivors [7]. These cytokines are produced by inflammatory macrophages which have been 
implicated in the cytokine storm. This is similar to previous outbreaks of MERS and SARS 
2002-3 in terms of having high proinflammatory cytokines in patients with severe disease 
[27]. 
 
MANAGEMENT OF PEDIATRIC COVID-19 
Upon suspicion of COVID-19 infection, immediate Infection prevention control (IPC) 




protective equipment (PPE), safe waste management and cleaning and disinfection of 
equipment must be followed as per the guidelines issued by the MOHFW [2]. 
For the few children who will require admission to a healthcare facility, the cornerstone of 
management is supportive therapy including adequate nutrition and calorie intake, fluid and 
electrolyte management and oxygen supplementation. Communication with parents and 
alleviating anxiety is an important part of management. In adults with severe COVID-19, early 
intubation and mechanical ventilation with lung protective strategies and prone positioning has 
been recommended [20]. Antibiotics may be indicated if bacterial super-infection is suspected.  
There are no randomized clinical trial data to guide treatment of the very few children 
that present with life-threatening COVID-19 including severe pneumonia, ARDS, sepsis and 
septic shock. Hence, the World Health Organization has not recommended any specific 
treatment for children until the results of ongoing clinical trials are available. We strongly 
believe that clinical trials of all therapeutic agents for COVID-19 are needed in children as 
well. It is important that when such clinical trials are open, children are treated only in the 
context of clinical trials and not outside these. In the absence of data from these trials, 
clinicians may be left in the difficult scenario of deciding whether to pursue treatment with 
antiviral drugs and immunomodulatory therapies for children with severe COVID-19. A 
relatively new antiviral drug being tested in adults with COVID-19 is remdesivir, which in 
combination with chloroquine has been found to inhibit SARS-CoV-2 growth in vitro [28]. 
Interferon alpha-2b and oral lopinavir/ritonavir together with corticosteroids for complications 
and intravenous immunoglobulin for severe cases has been recommended in one report in 
China [29]. A HIV test should be performed before commencing antiviral treatment, in 
particular lopinavir/ritonavir. 
The MOHFW has allowed off label use of hydoxychloroquine in combination with 




treatments are not currently recommended in children below the age of 12 years. 
Corticosteroids are not routinely recommended and might exacerbate COVID-19 associated 
lung injury [30]. Ivermectin, the broad spectrum anti-parasitic agent, has in-vitro antiviral 
action against SARS-CoV-2 [31]. 
Owing to the cytokine storm syndrome in COVID-19, there may potentially be a role 
of immunomodulators in treating patients with severe infections to ameliorate pulmonary 
inflammation and hopefully improve mortality. There is an established role of anakinra (IL-1 
blockade) in survival benefit of patients with hyperinflammation, without increased adverse 
events [8]. A multicenter randomized control trial (RCT) of the IL-6 receptor blocker, 
Tocilizumab is in progress in China for adults with COVID-19 pneumonia and raised IL-6 
levels (ChiCTR2000029765) [32]. There may also potentially be a role of janus kinase 
inhibitors (JKI) since these drugs block downstream inflammatory pathways and may alter 
cellular viral entry [33].  
A suggested management algorithm based on the limited observational data from 
adults is depicted in figures 1-3. It is important to note that very few children with COVID-19 
are likely to need any specific therapy other than supportive treatment, and the decision to 
start antiviral or immunomodulatory treatment should therefore be made carefully in 
consultation with experts in paediatric infectious disease and immunology. Given that severe 
COVID-19 appears very rare in children, an important part of this assessment is ascertaining 
whether a positive RT-PCR for SARS-CoV-2 is a clinically important factor in explaining the 
child’s condition, or whether more occult pathology may be responsible.  
For neonatal management of COVID-19 infected mothers, it is recommended to have a 
separate room adjacent to the delivery room for neonatal resuscitation or for resuscitation staff 
to maintain at least a 2 meter gap between the infected mother and newborn [34]. Only 




meticulous hand hygiene and wearing a mask. Standard neonatal resuscitation measures are to 
be followed and positive pressure ventilation if needed should be provided by a self-inflating 
bag and mask rather than a T-piece resuscitator. If the baby requires intensive care, a single 
patient room is ideal preferably with negative pressure. The baby should be tested at 24 hours 
of life and repeat testing should be performed at 48 hours. 
Antivirals/hydroxychloroquine/steroids or Intravenous immunoglobulin (IVIG) should not be 
administered to the newborn. The baby should then be tested every 48-72 hours until 2 
consecutive negative tests. It is critical that breastfeeding should be encouraged with the 
mother wearing a mask. The baby should be vaccinated prior to discharge from the hospital. 
IMPACT ON IMMUNOSUPPRESSED CHILDREN 
Data on children with immunocompromised conditions and COVID-19 are scarce, but severe 
disease may be more common in adults with cancer [35]. Despite concerns that 
immunocompromised children may have severe infection analogous to infection with 
adenovirus, rhinovirus, influenza, respiratory syncytial virus, and experience from previous 
pandemics (such as influenza H1N1), Antiga, et al. [36] described that children who were 
immunocompromised were not at greater risk of severe COVID-19, probably owing to the fact 
that a functional host innate immune response is the main driver for lung damage. In Bergamo, 
among 200 transplant recipients including 10 inpatients, 100 with autoimmune liver disease 
and three undergoing chemotherapy for hepatoblastoma (inpatients), none had clinical 
pulmonary disease, despite the fact that 3 patients tested positive for SARS-CoV-2, suggesting 
that the immunocompromised may be protected by their weaker immune response. No data is 
available on severity of COVID-19 infection in children with malnutrition, rheumatic heart 







Several vaccines against SARS-CoV-2 are in development; however, it remains unclear when 
a successful vaccine might be rolled out. Studies on factors responsible for immune 
dysregulation may provide insights into developing vaccines capable of inducing durable 
protective immunity and avoiding vaccine-related adverse events.  
This unprecedented pandemic should prompt improved global surveillance of 
infectious diseases, as well as cooperation and communication so that the global society 
remains interconnected and limits the spread of this outbreak.  
Lastly, we fear the greatest impact on children from COVID-19 is likely to be delayed 
presentation of other childhood illnesses due to fear and ignorance amongst parents/families. 
This coupled with the impact of economic uncertainty on those in the low socio-economic 
strata, is likely to have a greater adverse impact on child health in India in these uncertain 
times. 
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Figure 2: Suggested algorithm for case management of confirmed COVID-19 (Adapted from 

















Figure 3: Medications for COVID-19 
 
 
 
 
 
 
 
 
 
 
